AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33944875
Drug: Half-dose csDMARDs
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose csDMARDs (n=80)
Trial: 33944875
Drug: Stable-dose csDMARDs
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable-dose csDMARDs (n=80)
Trial: 35986131
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of Mothers and Babies (MB) intervention (attendance at >50% of MB sessions)
Trial: 35986131
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of Mothers and Babies (MB) intervention
Trial: 36214216
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg ensovibep
Trial: 36214216
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ensovibep
Trial: 33721561
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (n=644)
Trial: 33721561
Drug: Chemotherapy (n=749)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (n=749)
Trial: 33721561
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (n=748)
Trial: 33721561
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in women aged ≤50 years (n=464)
Trial: 33721561
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy in women aged ≤50 years (n=464)
Trial: 33721561
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in women aged >50 years (n=894)
Trial: 33721561
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy in women aged >50 years (n=894)
Trial: 33721561
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in node-negative patients (n=699)
Trial: 33721561
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy in node-negative patients (n=699)
Trial: 33721561
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in patients with 1-3 positive nodes (n=658)
Trial: 33721561
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy in patients with 1-3 positive nodes (n=658)
Trial: 33144321
Drug: Anti-N antibodies
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-N antibodies
Trial: 32404126
Drug: Solution Focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution Focused Brief Therapy (SFBT), 2-4 sessions
Trial: 33438238
Drug: Biological determinist
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological determinist message
Trial: 35330830
Drug: Neostigmine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.2 mg/h for 120 h)
Trial: 32990529
Drug: Dry Needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry Needling with Intramuscular Electrical Stimulation (DN/IMES)
Trial: 32048316
Drug: Nurse-led supportive
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led supportive intervention, details on dosage and duration not specified.
Trial: 32971161
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of celery seed, 3 times a day for 6 weeks
Trial: 32971161
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of celery seed
Trial: 33903890
Drug: Single hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single hyperbaric oxygen treatment
Trial: 32885585
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg thrice daily + 150 mg/day CC for 5 days
Trial: 34670665
Drug: Cisplatin (DDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (DDP) at IC50 (3.586 mg/L) for 48 hours
Trial: 34670665
Drug: Cisplatin (DDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (DDP) at IC50 (3.586 mg/L) combined with 20 μmol/L PD98059 for 48 hours
Trial: 34670665
Drug: 20 μmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μmol/L PD98059 for 48 hours
Trial: 34942135
Drug: Memantine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (20 mg/day orally)
Trial: 33726841
Drug: MEDPass administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MEDPass administration of ONS (50 ml four times per day)
Trial: 33726841
Drug: Conventional administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional administration of ONS (between meals)
Trial: 33726841
Drug: MEDPass administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MEDPass administration of ONS
Trial: 34238381
Drug: SLC45A2 rs183671-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLC45A2 rs183671-G allele
Trial: 35322474
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (20 mL of 0.375% ropivacaine and 0.5 mcg/kg of clonidine)
Trial: 35322474
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (150 mcg preservative-free morphine with 2 mL of normal saline)
Trial: 36088901
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid (1,000 mg in total)
Trial: 36088901
Drug: Low-dose tranexamic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tranexamic acid (500 mg in total)
Trial: 34914232
Drug: Microsurgical varicocelectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microsurgical varicocelectomy followed by oral administration of Danhong Tongjing Prescription (DTP) for 90 days
Trial: 33043615
Drug: Pelvic EBRT
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic EBRT combined with chemotherapy; 61% for Stage IIIA cases, 88% for IIIC1 cases.
Trial: 38013135
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant treatment
Trial: 35166029
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser + topical triamcinolone (TA)
Trial: 33640890
Drug: Low-dose hydroxychloroquine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hydroxychloroquine therapy
Trial: 33039952
Drug: DMB (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMB (vitamin D3 1000 IU/d, magnesium 150 mg/d, vitamin B12 500 mcg/d)
Trial: 35033180
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of PCV at 6 weeks with a booster at 9 months (1+1 schedule)
Trial: 35033180
Drug: Three primary
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three primary doses of PCV at 6, 10, and 14 weeks (3+0 schedule)
Trial: 35033180
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of PCV with yellow fever vaccine at 9 months
Trial: 33164984
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) treatment (1 g/m2)
Trial: 33164984
Drug: Multivariable model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivariable model including ALL subtype, SLC19A1/(ABCC1 + ABCC4) transporter ratio, MTX infusion time, FPGS mRNA expression, and MTX systemic clearance
Trial: 33164984
Drug: Longer infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Longer infusion time (24 h vs. 4 h)
Trial: 32873926
Drug: Continuous energy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous energy restriction (CER) - 75% energy requirements daily
Trial: 36166026
Drug: Serplulimab plus
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab plus chemotherapy (4.5 mg/kg intravenously every 3 weeks)
Trial: 36166026
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (intravenously every 3 weeks)
Trial: 37215110
Drug: Serplulimab plus
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab plus chemotherapy
Trial: 33957881
Drug: Alternate-day oral
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day oral administration of S-1 (80 mg/m2/day) for 4 days a week (Group A)
Trial: 33957881
Drug: 2-week oral
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week oral administration of S-1 (80 mg/m2/day) followed by 1 week of rest (Group B)
Trial: 32007688
Drug: Serum PCDD/Fs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PCDD/Fs (fg TEQ/g lipid)
Trial: 33522931
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 mg oral arm
Trial: 34559992
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg on day 1, followed by 5 mg/kg per day on days 2-5)
Trial: 33812497
Drug: Chemotherapy (mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (mFOLFOX6 or FOLFIRI)
Trial: 33119613
Drug: Rintatolimod treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rintatolimod treatment in the Target Subset (n = 75)
Trial: 36310098
Drug: Long intervals
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long intervals (L‐INT; n = 7)
Trial: 35637624
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg CBD
Trial: 37802088
Drug: Efruxifermin 28
RxNorm normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efruxifermin 28 mg
Trial: 38447814
Drug: Efruxifermin 50
RxNorm normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efruxifermin 50 mg
Trial: 34239138
Drug: Efruxifermin 70
RxNorm normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efruxifermin 70 mg
Trial: 34798295
Drug: Methylnaltrexone (MNTX)
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Methylnaltrexone (MNTX) administered perioperatively
Trial: 34825104
Drug: High-Intensity Interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Interval Training (HIIT) applied in the first 10–15 min of each Physical Education class, twice a week for 16 weeks, with 14 to 20 all-out bouts intervals and a 2:1 work to rest ratio.
Trial: 35964210
Drug: Robotic-assisted gait
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic-assisted gait training (30 minutes) + conventional physical therapy (30 minutes)
Trial: 35964210
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (60 minutes)
Trial: 32943843
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg, then 2 mg/kg/h, IV)
Trial: 32818325
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour group therapy (CBGT)
Trial: 35469428
Drug: LT4 oral
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 oral solution (Tirosint®‐SOL) 600 mcg taken 15 minutes before a high-fat high-calorie meal
Trial: 35469428
Drug: LT4 oral
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 oral solution (Tirosint®‐SOL) 600 mcg taken 30 minutes before a high-fat high-calorie meal
Trial: 34582369
Drug: Linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin (5 mg/d)
Trial: 35007127
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (InO) 0.8 mg/m2 intravenously on day 1 and 0.5 mg/m2 on days 8 and 15 of a 28-day cycle.
Trial: 34143803
Drug: Nguvu intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nguvu intervention (8 weekly sessions delivered by lay refugee incentive workers)
Trial: 34212187
Drug: Standard 12-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 12-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor
Trial: 35339652
Drug: Massage chair
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage chair used twice a day for 6 months
Trial: 32665039
Drug: Hydroxychloroquine 400mg
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400mg orally once daily for 90 days
Trial: 32665039
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets visually identical to hydroxychloroquine) orally once daily for 90 days
Trial: 616115985
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg daily (n=44)
Trial: 36031355
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg (group M)
Trial: 36031355
Drug: Dexmedetomidine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.5 μg/kg (group H)
Trial: 36031355
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg/kg (group L)
Trial: 32019389
Drug: Dance intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dance intervention (twice-weekly sessions for 8 months)
Trial: 32931958
Drug: Dual-antiplatelet therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-antiplatelet therapy
Trial: 36148447
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication (RM) only
Trial: 35036624
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (PT) once monthly for 6 months
Trial: 33544206
Drug: 16 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g/d native inulin (prebiotic)
Trial: 33494132
Drug: Aronia juice
RxNorm normalized name: Aronia melanocarpa fruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aronia juice (AJ) with 1177.11 mg polyphenols/100 mL (n = 22)
Trial: 33494132
Drug: Aronia juice
RxNorm normalized name: Aronia melanocarpa fruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aronia juice (MJ) with 294.28 mg polyphenols/100 mL (n = 20)
Trial: 34052458
Drug: Health literacy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health literacy evaluation using the Rapid Estimate of Adult Literacy in Medicine (REALM)
Trial: 35648294
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg implanted into the socket
Trial: 33431491
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of CNM-Au8 once daily for 36 weeks
Trial: 32998143
Drug: Eplerenone 50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg monotherapy
Trial: 32998143
Drug: Eplerenone/Ramipril 50/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone/Ramipril 50/10 mg combination therapy
Trial: 36123724
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate injection (2 ml)
Trial: 36123724
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (2 ml)
Trial: 33045140
Drug: Intranasal capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal capsaicin 0.1mM
Trial: 32173018
Drug: High concentrate
RxNorm normalized name: A Mulsin High Concentrate 300,000unit Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentrate intake (>350 g/d)
Trial: 32173018
Drug: Low concentrate
RxNorm normalized name: NIACINAMIDE 2 g in 100 mL / ADENOSINE 0.04 g in 100 mL TOPICAL LIQUID [Hydrating all in one glow concentrate ampoule]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concentrate intake (≤350 g/d)
Trial: 34489274
Drug: Sputum samples
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sputum samples collected at baseline and monthly to week 24
Trial: 34489274
Drug: PK and
RxNorm normalized name: ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PK and PKPD models developed for each drug
Trial: 34516535
Drug: Inflammation-adjusted ferritin
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inflammation-adjusted ferritin concentrations using a higher ferritin cut-off point (<30 g/L)
Trial: 34516535
Drug: Inflammation-adjusted ferritin
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inflammation-adjusted ferritin concentrations excluding subjects with inflammation (C-reactive protein >5 mg/L or a1-acid glycoprotein >1 g/L)
Trial: 34516535
Drug: Proportion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proportion of children with inflammation according to C-reactive protein concentrations >5 mg/L
Trial: 34516535
Drug: Proportion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proportion of children with inflammation according to a1-acid glycoprotein concentrations >1 g/L
Trial: 35840306
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic administration 1 week prior to tissue culture collection
Trial: 35840306
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic administration 3 days prior to tissue culture collection
Trial: 35840306
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic administration 1 day prior to tissue culture collection
Trial: 35840306
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic administration 1 day after tissue culture collection
Trial: 34472896
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive remediation therapy (CRT)
Trial: 34431929
Drug: Floral therapy
RxNorm normalized name: floralozone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floral therapy (Five Flower floral essence)
Trial: 35962639
Drug: Midazolam/Ketamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam/Ketamine (30 to 50 μg/kg and 0.25 to 1 mg/kg)
Trial: 35962639
Drug: Propofol/Fentanyl (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol/Fentanyl (0.5 to 1 mg/kg and 0.5 to 1 mg/kg)
Trial: 35389583
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light and radiofrequency therapy
Trial: 35220312
Drug: Propolis alone
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis alone (1,000 mg/day)
Trial: 35220312
Drug: Propolis (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis (1,000 mg/day) plus melatonin (20 mg/day)
Trial: 35220312
Drug: Melatonin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin alone (20 mg/day)
Trial: 36411426
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine (0.4 ml/kg)